» Articles » PMID: 34781907

Effectiveness of the German Disease Management Programs: Quasi-experimental Analyses Assessing the Population-level Health Impact

Overview
Publisher Biomed Central
Specialty Public Health
Date 2021 Nov 16
PMID 34781907
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In 2002-2003 disease management programs (DMPs) for type 2 diabetes and coronary heart disease were introduced in Germany to improve the management of these conditions. Today around 6 million Germans aged 56 and older are enrolled in one of the DMPs; however, their effect on health remains unclear.

Methods: We estimated the impact of German DMPs on circulatory and all-cause mortality using a synthetic control study. Specifically, using routinely available data, we compared pre and post-intervention trends in mortality of individuals aged 56 and older for 1998-2014 in Germany to trends in other European countries.

Results: Average circulatory and all-cause mortality in Germany and the synthetic control was 1.63 and 3.24 deaths per 100 persons. Independent of model choice, circulatory and all-cause mortality decreased non-significantly less in Germany than in the synthetic control; for the model with a 3 year time lag, for example, by 0.12 (95%-CI: - 0.20; 0.44) and 0.22 (95%-CI: - 0.40; 0.66) deaths per 100 persons, respectively. Further main analyses, as well as sensitivity and subgroup analyses supported these results.

Conclusions: We observed no effect on circulatory or all-cause mortality at the population-level. However, confidence intervals were wide, meaning we could not reject the possibility of a positive effect. Given the substantial costs for administration and operation of the programs, further comparative effectiveness research is needed to clarify the value of German DMPs for type 2 diabetes and CHD.

Citing Articles

Patients' and stakeholders' experiences of a personalized self-management SUPport program (P-SUP) for patients with type 2 diabetes mellitus and/or coronary heart disease: a qualitative process evaluation : Maximilian Scholl.

Scholl M, Amerkamp J, Chermette C, Frank F, Funke C, Giesen L BMC Public Health. 2024; 24(1):2566.

PMID: 39300369 PMC: 11414288. DOI: 10.1186/s12889-024-20034-6.


Correction to: Effectiveness of the German disease management programs: quasi-experimental analyses assessing the population-level health impact.

Burns J, Kurz C, Laxy M BMC Public Health. 2021; 21(1):2223.

PMID: 34876082 PMC: 8650301. DOI: 10.1186/s12889-021-12299-y.

References
1.
Smith W, Lee A, Crombie I, Tunstall-Pedoe H . Control of blood pressure in Scotland: the rule of halves. BMJ. 1990; 300(6730):981-3. PMC: 1662684. DOI: 10.1136/bmj.300.6730.981. View

2.
Grol R . Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care. 2001; 39(8 Suppl 2):II46-54. DOI: 10.1097/00005650-200108002-00003. View

3.
Pimouguet C, Le Goff M, Thiebaut R, Dartigues J, Helmer C . Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. CMAJ. 2010; 183(2):E115-27. PMC: 3033953. DOI: 10.1503/cmaj.091786. View

4.
Norris S, Nichols P, Caspersen C, Glasgow R, Engelgau M, Jack L . The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med. 2002; 22(4 Suppl):15-38. DOI: 10.1016/s0749-3797(02)00423-3. View

5.
Fuchs S, Henschke C, Blumel M, Busse R . Disease management programs for type 2 diabetes in Germany: a systematic literature review evaluating effectiveness. Dtsch Arztebl Int. 2014; 111(26):453-63. PMC: 4101529. DOI: 10.3238/arztebl.2014.0453. View